Our key ingredients for a successful oligonucleotide drug development
The therapeutic usage of oligonucleotide-based drugs is growing. Moving from rare diseases to chronic indications, the market demand for oligonucleotide therapeutics keeps increasing and is coupled by the emergence of new challenges related to scalability,...
Innovation transforming oligonucleotide manufacturing
One of Bachem’s mission is to provide excellence to its customers and be a major player in their success. To achieve this, we are constantly advancing our technologies and manufacturing processes. Throughout the years, we have developed technical leadership,...
Entering strategic collaboration with Lilly to manufacture oligo-based drug substances
Strategic collaboration with Lilly to develop innovative and efficient processing solutions for the manufacture of oligonucleotide-based drug substances. The annual order volume has the potential to achieve around CHF 100 million, depending on Bachem reaching...
Bachem’s new facilities for large-scale oligonucleotide manufacturing
Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago. Initially focusing on rare diseases, oligonucleotide therapeutics are moving into more common chronic indications like asthma,...